RT Journal Article
SR Electronic
T1 Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 335
OP 339
DO 10.21873/anticanres.13957
VO 40
IS 1
A1 SHIOTA, MASAKI
A1 NAKAMURA, MOTONOBU
A1 YOKOMIZO, AKIRA
A1 TOMODA, TOSHIHISA
A1 SAKAMOTO, NAOTAKA
A1 SEKI, NARIHITO
A1 HASEGAWA, SHUJI
A1 YUNOKI, TAKAKAZU
A1 HARANO, MASAHIKO
A1 KUROIWA, KENTARO
A1 ETO, MASATOSHI
YR 2020
UL http://ar.iiarjournals.org/content/40/1/335.abstract
AB Background/Aim: The novel taxane cabazitaxel has been shown to exert excellent anticancer effects after androgen receptor axis-targeting (ARAT) agents in clinical data, but not in in vitro data. We investigated the clinical outcome of cabazitaxel chemotherapy after docetaxel according to use of ARAT agents. Patients and Methods: Prostate specific antigen (PSA) response, progression-free survival, and overall survival were compared between cases with and without prior use of ARAT agents in 74 Japanese patients with metastatic castration-resistant prostate cancer treated with cabazitaxel chemotherapy. Results: Background characteristics were comparable between patients with and without prior use of ARAT agents. PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. Conclusion: No detrimental effects of prior ARAT agents on clinical outcome were observed for cabazitaxel chemotherapy in the post-docetaxel setting, suggesting that cabazitaxel can be expected to remain active even after ARAT agent therapy.